Earlier Insights and Deeper Knowledge
The earlier you get answers in drug R&D, the more equipped you are to make confident decisions on the next steps of your clinical program.
Utilizing multiple fat and muscle biomarkers offers you an unrivalled level of detail that can help you analyze complex metabolic disease processes, the efficacy and impact of a drug, and changes over the course of disease—so you can get the key information you need as early as possible.
Drug Impact and Efficacy
We understand that you need to know if your drug candidate works and if it is safe—as efficiently and economically as possible.
Our services can help you detect treatment efficacy and identify non-responders early.
Further, our precise muscle and fat biomarkers can help you better characterize individuals with metabolic diseases at baseline, monitor interventional effects, and detect small physiological changes throughout the body.
Disease Course and Longitudinal Tracking
Understanding how metabolic diseases develop and change over time is critical for developing top-tier therapeutics. Our body composition biomarkers and automated image analysis can help you expand your team’s knowledge of how metabolic diseases develop and change throughout disease course.
Our technology delivers volumetric muscle and fat measurements—generating a more comprehensive assessment of what is happening throughout the body—unlike other less accurate techniques such as BIA and DXA.
Patient Recruitment and Stratification
Defining inclusion and exclusion criteria can be complex, and finding the right individuals for your clinical trial can be time-consuming—AMRA helps simplify this process.
With our biomarkers, you can easily phenotype and stratify populations to facilitate more appropriate patient recruitment and smaller, more efficient clinical trials.